Blog | BioInformant

Bahamas Summit to Take Deep Dive into Stem Cell Innovation and Digital Health

September 10, 2018 By Cade Hildreth, Founder & President Leave a Comment

There’s a new arena for stem cell innovation and digital health advancement. Believe it or not, it’s replete with crystal clear waters and powder white sands. It’s called the 2018 HEALinc Future Health Innovation Summit.

The Summit is hosted in The Bahamas, a safe haven for intellectual property discussions and home to progressive legislation in the region promoting stem cell research. With an impressive faculty of the best and brightest minds in translational medicine, the Summit is a “must attend” event. [Read more…]

Novartis Receives Health Canada Approval of its CAR-T cell therapy, Kymriah™

September 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

Kymriah, the first chimeric antigen receptor T cell (CAR-T) therapy approved in Canada, is manufactured individually for each patient
Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL indications

DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]

Interview with Dr. Desirée Cox, CEO of the HEALinc Future Health Innovation Summit

September 6, 2018 By Cade Hildreth, Founder & President Leave a Comment

Dr. Desirée Cox, MD, PhD is a thought leader in future health innovation. She is a Rhodes Scholar, medical doctor, published author and contemporary visual artist whose work has been shown in exhibitions all over the world. She is also the founder and CEO of The HEALinc Innovation Incubator and the HEALinc Future Health Innovation Summit.

The 2018 Inaugural Summit takes place this year, October 7^th-9^th at the Melia Hotel in Nassau, Bahamas.

Dr. Cox has earned degrees from McGill University (Canada), Oxford University (UK) and Cambridge University (UK). She is an honorary professor of the Rutgers Graduate School of Biomedical Sciences and a former university professor and honorary professor of creativity, health and wellbeing at the University of Exeter (UK). She has also been recognized by the British Medical Journal as a ‘Renaissance Woman’ for her application of psychological medicine to real world problems. [Read more…]

Celularity Acquires CariCord, Adds Biosourcing Assets, Establishes Relationship with ClinImmune Labs

September 4, 2018 By Cade Hildreth, Founder & President Leave a Comment

WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]

Cynata’s iPSC-derived Cell Therapeutic
(CYP-001) Meets Safety & Efficacy Endpoints

September 3, 2018 By Cade Hildreth, Founder & President 2 Comments

Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Cynata is the only company in the world that can mass-produce therapeutic mesenchymal stem cells deriving from a single donor at a consistent quality and affordable cost. [Read more…]